A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients
Condition: Metastatic Pancreatic Ductal Adenocarcinoma Intervention: Drug: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine Sponsors: Pancreatic Cancer Action Network; Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials